21064 ⎘
Medicinal preparations containing antigens or antibodies; Vertebrate antigens Preparations to induce tolerance to non-self, e.g. prior to transplantation
METHOD FOR PRODUCING LOW-ANTIGENIC CELL
#2GLYCOTARGETING THERAPEUTICS
#3MEASURING THE PROGRESS OF CARDIAC XENOGRAFT IMMUNE REJECTION
#4USE OF VIRUS-LIKE PARTICLES IN VACCINATION
#5GLYCOTARGETING THERAPEUTICS
#6NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION
#7GLYCOTARGETING THERAPEUTICS
#8TOLEROGENIC COMPOSITION
#9SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES
#10COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC TOLERANCE
#11ANTI-ASGR1 POLYPEPTIDES AND METHODS OF USE FOR IMMUNE TOLERANCE
#12METHODS AND COMPOSITIONS FOR CAS IMMUNE TOLERANCE INDUCTION TO SUPPORT CRISPR-CAS IN VIVO GENE EDITING
#13Tolerizing Immune Modifying Nanoparticles for Overcoming the Immunogenicity of Therapeutic Vectors and Proteins
#14IMMUNE TOLERANCE INDUCTION TO VIRAL CAPSIDS
#15SINGLE-AND MULTI-EPITOPE PEPTIDE AND MRNA VACCINES TO GENERATE TOLEROGENIC EFFECTS FOR ALLERGIC AND AUTOIMMUNE DISEASE BY TARGETING LIVER SINUSOIDAL ENDOTHELIAL CELLS
#16PHOSPHOSERINE CONTAINING COMPOSITIONS FOR IMMUNE TOLERANCE INDUCTION
#17GLYCOTARGETING THERAPEUTICS
#18INDUCIBLE REGULATORY T-CELL GENERATION FOR HEMATOPOIETIC TRANSPLANTS
#19IMMUNE CELL SELECTION, EXPANSION, AND USE
#20COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS
#21PROTEIN-BASED T-CELL RECEPTOR KNOCKDOWN
#22ESTABLISHMENT AND TRANSLATION OF NEAR-ZERO IMMUNOSUPPRESSION STRATEGY FOR ORTHOTOPIC LIVER ALLOGRAFT TRANSPLANTATION
#23INTRACELLULAR DELIVERY OF BIOMOLECULES TO INDUCE TOLERANCE
#24Radiohalogenated Agents for in Situ Immune Modulated Cancer Vaccination
#25ERYTHROCYTE-BINDING THERAPEUTICS
#26POLYNUCLEOTIDES ENCODING INTEGRIN BETA-6 AND METHODS OF USE THEREOF
#27COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
#28METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
#29Peptide Conjugated Particles
#30COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCER
#31UNIVERSAL DONOR STEM CELLS AND RELATED METHODS
#32UNIVERSAL DONOR STEM CELLS AND RELATED METHODS
#33ENZYMATICALLY METHYLATED DNA AND METHODS OF PRODUCTION AND THERAPEUTIC USE
#34NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF
#35NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF
#36COMPOSITIONS AND METHOD FOR TREATING ACUTE RADIATION SYNDROME
#37METHODS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
#38ERYTHROCYTE-BINDING THERAPEUTICS
#39TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY
#40IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF
#41IMMUNE TOLERANCE INDUCTION AND ERADICATION OF ANTI-DRUG ANTIBODIES (ADA) TO THERAPEUTIC FACTOR VIII
#42STRATEGIES TO PREVENT AND/OR TREAT IMMUNE RESPONSES TO SOLUBLE ALLOFACTORS
#43METHODS AND SYSTEMS FOR HANDLING AUTOIMMUNE DISORDERS
#44UNIVERSAL DONOR CELLS AND RELATED METHODS
#45IMMUNOGENIC PEPTIDES AND THEIR USE IN TRANSPLANTATION
#46TOLEROGENIC SYNTHETIC NANOCARRIERS
#47SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES
#48GENETICALLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPY
#49UNIVERSAL DONOR STEM CELLS AND RELATED METHODS
#50TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION
#51METHODS AND COMPOUNDS FOR ELIMINATING IMMUNE RESPONSES TO THERAPEUTIC AGENTS
#52PEPTIDE CONJUGATED PARTICLES
#53IMMUNE-MODIFYING NANOPARTICLES FOR THE TREATMENT OF INFLAMMATORY DISEASES
#54VETO CELLS GENERATED FROM MEMORY T CELLS
#55IMMUNOENGINEERING BIOMATERIALS FOR TREATMENT OF GRAFT REJECTION
#56T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF
#57METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
#58Universal donor stem cells and related methods
#59TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
#60TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES
#61TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY
#62Universal donor stem cells and related methods
#63Universal donor stem cells and related methods
#64METHODS FOR INDUCING SELECTIVE APOPTOSIS
#65TREATMENT OF AUTOIMMUNITY AND TRANSPLANT REJECTION THROUGH ESTABLISHMENT AND/OR PROMOTION OF TOLEROGENIC PROCESSES BY FIBROBLAST-MEDIATED REPROGRAMMING OF ANTIGEN PRESENTING CELLS
#66GLYCOTARGETING THERAPEUTICS
#67GLYCOTARGETING THERAPEUTICS
#68GLYCOTARGETING THERAPEUTICS
#69GLYCOTARGETING THERAPEUTICS
#70COMPOUNDS FOR THE INDUCTION OF ANTIGEN-SPECIFIC IMMUNE TOLERANCE
#71METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
#72Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
#73POLYMERIC NANOPARTICLES THAT TARGET LIVER SINUSOIDAL ENDOTHELIAL CELLS TO INDUCE ANTIGEN-SPECIFIC IMMUNE TOLERANCE
#74IMMUNE TOLERIZATION AGENTS AND POTENTIATORS
#75METHODS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
#76Combined organ and hematopoietic cells for transplantation tolerance of grafts
#77METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSES
#78IMMUNOACTIVE MICROPARTICLES AND USES THEREOF
#79PEPTIDE ANTIGENS AND USES THEREOF
#80Cell populations having immunoregulatory activity, method for isolation and uses
#81METHOD OF INDUCING ANTIGEN-SPECIFIC TOLERANCE IN A SUBJECT BY ADMINISTERING A COMPOSITION COMPRISING AN APOPTOTIC BODY SURROGATE AND COUPLED IMMUNODOMINANT ANTIGENIC EPITOPES ASSOCIATED WITH AUTOIMMUNE DISEASE
#82COMPOSITIONS AND METHODS FOR TREATING ACUTE RADIATION SYNDROME
#83Composition comprising vitamin A and non digestible oligosaccharides
#84COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
#85Compositions Comprising Apoptotic Signaling and Methods for Induction of Antigen-Specific Tolerance
#86METHOD FOR LARGE-SCALE PRODUCTION OF ALLOSPECIFIC TYPE 1 REGULATORY TREGS (TR1) STABLE IN THE PRESENCE OF PROINFLAMMATORY CYTOKINES WITH THERAPEUTIC POTENTIAL IN TRANSPLANTATION
#87COMPOSITIONS AND METHODS FOR INDUCING ANTIGEN-SPECIFIC TOLERANCE
#88CONDITIONING AGENTS FOR USE IN ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION
#89Universal donor stem cells and related methods
#90METHODS FOR INDUCING IMMUNE TOLERANCE
#91Immunotherapeutic molecules and uses thereof
#92Genetically modified anti-third party central memory T cells and use of same in immunotherapy
#93ISOLATED MHC-DERIVED HUMAN PEPTIDES AND USES THEREOF FOR STIMULATING AND ACTIVATING THE SUPPRESSIVE FUNCTION OF CD8+CD45RCLOW TREGS
#94METHODS AND MATERIALS FOR REDUCING CARDIAC XENOGRAFT REJECTION
#95POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
#96IMMUNOGENIC PEPTIDES WITH IMPROVED OXIDOREDUCTASE MOTIFS
#97MODULATION OF ANTIGEN IMMUNOGENICITY BY DELETING EPITOPES RECOGNIZED BY NKT CELLS
#98PHOSPHOSERINE CONTAINING COMPOSITIONS FOR IMMUNE TOLERANCE INDUCTION
#99SUBSTANCES, VACCINES AND METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF TRANSPLANT REJECTION
#100BACTERICIDAL/PERMEABILITY INCREASING PROTEIN FOR USE IN A METHOD OF IMMUNIZATION, PREFERABLY AS AN ADJUVANT IN A METHOD OF VACCINATION
#101INDUCIBLE REGULATORY T-CELL GENERATION FOR HEMATOPOIETIC TRANSPLANTS
#102Universal donor stem cells and related methods
#103Erythrocyte-binding therapeutics
#104USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
#105IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF
#106Veto cells generated from memory T cells
#107IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF
#108Combined organ and hematopoietic cells for transplantation tolerance of grafts
#109NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION
#110INTRACELLULAR DELIVERY OF BIOMOLECULES TO INDUCE TOLERANCE
#111Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
#112Erythrocyte-binding therapeutics
#113Methods for allogenic hematopoietic stem cell transplantation
#114Methods for allogenic hematopoietic stem cell transplantation
#115METHODS OF INDUCING IMMUNE TOLERANCE AND REDUCING ANTI-DRUG ANTIBODY RESPONSE
#116METHODS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
#117NOVEL COMPLEXES OF TYPES OF MHC CLASS II THAT BIND TO COLLAGEN TYPE II PEPTIDES AND THEIR USE ON DIAGNOSIS AND TREATMENT
#118CONTROLLED RELEASE FORMULATIONS FOR THE INDUCTION AND PROLIFERATION OF BLOOD CELLS
#119Peptide conjugated particles
#120Radiohalogenated agents for in situ immune modulated cancer vaccination
#121Protein-based T-cell receptor knockdown
#122DNA VACCINES AND METHODS FOR THE PREVENTION OF TRANSPLANTATION REJECTION
#123Citrullinated peptides that bind to types of MHC class II and their use on diagnosis and treatment
#124IMMUNE-MODIFYING NANOPARTICLES FOR THE TREATMENT OF INFLAMMATORY DISEASES
#125IMMUNE-MODIFYING NANOPARTICLES FOR THE TREATMENT OF INFLAMMATORY DISEASES
#126IMMUNOGENIC PEPTIDES AND THEIR USE IN TRANSPLANTATION
#127BIOFUNCTIONALIZED NANOPARTICLES AND USES THEREOF IN ADOPTIVE CELL THERAPY
#128Combined organ and hematopoietic cells for transplantation tolerance of HLA mismatched grafts
#129Nanoparticles for treatment of allergy
#130STRATEGIES TO PREVENT AND/OR TREAT IMMUNE RESPONSES TO SOLUBLE ALLOFACTORS
#131Compositions and methods for preventing and treating graft versus host disease
#132Novel Combinations for Antigen Based Therapy
#133Glycotargeting therapeutics
#134Glycotargeting therapeutics
#135Glycotargeting therapeutics
#136Glycotargeting therapeutics
#137Antigen-specific tolerance and compositions for induction of same
#138TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS
#139TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS
#140Compositions and methods for inducing immune tolerance
#141T REGULATORY CELLS AND USES THEREOF
#142METHODS OF TREATING A MAMMAL SUFFERING FROM OR SUSCEPTIBLE TO AN IMMUNE REACTION TO DRUG TREATMENT
#143METHODS OF TREATING GRAFT VERSUS HOST DISEASE (GVHD) OR EPIDERMOLYSIS BULLOSA (EB) WITH EXOSOMES
#144Compositions and Methods for Antigen-Specific Tolerance
#145METHODS FOR INDUCING SELECTIVE APOPTOSIS
#146ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE
#147Erythrocyte-binding therapeutics
#148PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF
#149HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof
#150Combined organ and hematopoietic cells for transplantation tolerance of grafts
#151Combined organ and hematopoietic cells for transplantation tolerance of grafts
#152ERYTHROID CELLS COMPRISING ARGINASE
#153ERYTHROID CELLS COMPRISING ARGININE DEIMINASE
#154Erythroid cells comprising phenylalanine ammonia lyase
#155Veto cells generated from memory T cells
#156ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE
#157ERYTHROID CELLS COMPRISING LYSINE OXIDASE
#158Universal donor stem cells and related methods
#159Combined organ and hematopoietic cells for transplantation tolerance of grafts
#160Vectors and methods for long-term immune evasion to prolong transplant viability
#161SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#162Peptide conjugated particles for the treatment of inflammation
#163Universal donor cells and related methods
#164COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS
#165Combined organ and hematopoietic cells for transplantation tolerance of grafts
#166Combined organ and hematopoietic cells for transplantation tolerance of grafts
#167Phosphoserine containing compositions for immune tolerance induction
#168Synthetic membrane-receiver complexes
#169DLL4-expressing cells and vaccine using the same
#170MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES
#171Intracellular delivery of biomolecules to induce tolerance
#172Combined organ and hematopoietic cells for transplantation tolerance of grafts
#173AQUAPORIN TOLERIZING VACCINES AND METHODS OF USE THEREOF
#174Combined organ and hematopoietic cells for transplantation tolerance of grafts
#175Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
#176Treatment of immune disease by mucosal delivery of antigens using genetically modified
#177METHODS AND COMPOSITIONS FOR ATTENUATING GENE EXPRESSION MODULATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
#178Immune-modifying nanoparticles for the treatment of inflammatory diseases
#179T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
#180IMMUNE CELL SELECTION, EXPANSION, AND USE
#181Inducible regulatory t-cell generation for hematopoietic transplants
#182University donor cells and related methods
#183Epitopes Related To Coeliac Disease
#184Skin microenvironment targeted delivery for promoting immune and other responses
#185Combined organ and hematopoietic cells for transplantation tolerance of HLA mismatched grafts
#186Use of modified Fc fragments in immunotherapy
#187Uses of expanded populations of hematopoietic stem/progenitor cells
#188Functionalized erythroid cells
#189Combined organ and hematopoietic cells for transplantation tolerance of grafts
#190Immunomodulatory properties of MAPCs and uses thereof
#191Glycotargeting therapeutics
#192Antigens and T cell epitopes from cockroach and methods of making and using same
#193Biofunctionalized nanoparticles and uses thereof in adoptive cell therapy
#194Glycotargeting therapeutics
#195METHODS FOR INDUCING SELECTIVE APOPTOSIS
#196SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#197Methods and compounds for eliminating immune responses to therapeutic agents
#198Methods for inducing selective apoptosis
#199Combined organ and hematopoietic cells for transplantation tolerance of grafts
#200METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
#201Combined organ and hematopoietic cells for transplantation tolerance of grafts
#202SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#203NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION
#204Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
#205Synthetic membrane-receiver complexes
#206Genetically modified anti-third party central memory T cells and use of same in immunotherapy
#207Methods of transplantation and disease treatment
#208Multimeric polypeptides of HLA-G including at least two alpha3 domains and pharmaceutical uses thereof
#209POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
#210Compositions and methods for reducing organ rejection by reducing heparan sulfate in donor transplants
#211Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
#212Combined organ and hematopoietic cells for transplantation tolerance of grafts
#213Combined organ and hematopoietic cells for transplantation tolerance of grafts
#214SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#215SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#216Antigen-specific tolerance and compositions for induction of same
#217Compositions for generation of immune tolerance to specific antigens
#218Compositions for inducing antigen-specific tolerance
#219Vectors and methods for long-term immune evasion to prolong transplant viability
#220Synthetic membrane-receiver complexes
#221Erythrocyte-binding therapeutics
#222Protein-based T-cell receptor knockdown
#223MATRIX-EMBEDDED TOLERANCE-PROMOTING ADJUVANTS FOR SUBCUTANEOUS IMMUNOTHERAPY
#224Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
#225Methods for diagnosing and reducing incidences of cardiac allograft rejection
#226EXPANSION OF ALLOANTIGEN-REACTIVE REGULATORY T CELLS
#227Synthetic membrane-receiver complexes
#228Radiohalogenated agents for in situ immune modulated cancer vaccination
#229COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC TOLERANCE
#230Modulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
#231Synthetic membrane-receiver complexes
#232COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING GRAFT VERSUS HOST DISEASE
#233B4GALNT2 knock out pig
#234TOLEROGENIC COMPOSITIONS AND METHODS
#235EPITOPES RELATED TO COELIAC DISEASE
#236GLYCOTARGETING THERAPEUTICS
#237CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES
#238CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES
#239Methods of Treating Graft Versus Host Disease (GVHD) or Epidermolysis Bullosa (EB)
#240Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient
#241POPULATION OF IMMUNOREGULATORY T CELLS SPECIFIC FOR AN IRRELEVANT ANTIGEN AND USES THEREOF FOR PREVENTING OR TREATING IMMUNE DISEASES
#242Isolated donor MHC-derived peptide and uses thereof
#243Compositions and methods for inducing immune tolerance
#244Inhibitors of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity
#245Combined organ and hematopoietic cells for transplantation tolerance of HLA mismatched grafts
#246Method for identifying and obtaining activated T-cells that have a demethylated Foxp3 TSDR region
#247STRATEGIES TO PREVENT AND/OR TREAT IMMUNE RESPONSES TO SOLUBLE ALLOFACTORS
#248Inflammation inhibiting compounds
#249Erythrocyte-binding therapeutics
#250METHODS OF EXPANDING EX VIVO NATURAL KILLER T (NKT) CELLS AND THERAPEUTIC USES THEREOF
#251DNA vaccines and methods for the prevention of transplantation rejection
#252Isolated donor MHC-derived peptide and uses thereof
#253Replacement gene tolerizing vectors and methods of use thereof
#254Compositions and methods for preparing a subject for organ or non-organ implantation
#255Glycotargeting therapeutics
#256Tolerogenic compositions comprising and uses thereof
#257Newly identified peptides for use in the induction of oral tolerance in young mammals
#258Methods for reducing immune responses
#259Compositions for inducing antigen-specific tolerance
#260Methods for induction of antigen-specific immune tolerance
#261Compositions for generating immune tolerance by targeting erythrocytes
#262IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF
#263Polynucleotide, polypeptide with immunosuppressive activity, expression cassette, expression vector, host cell, pharmaceutical composition, methods for producing a polypeptide with immunosuppressive activity and for preventing or treating conditions that require immunosuppression, and use of a polypeptide
#264Tolerogenic synthetic nanocarriers for allergy therapy
#265Epitopes related to coeliac disease
#266Allograft tolerance induction
#267Tolerogenic synthetic nanocarriers
#268Glycotargeting therapeutics
#269COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS
#270MANAGING IMMUNE RESPONSES IN TRANSPLANTATION
#271METHODS OF MODULATING THE NEGATIVE CHEMOTAXIS OF IMMUNE CELLS
#272ILT3 polypeptides and uses thereof
#273Complexes of types of MHC class II that bind to collagen type II peptides and their use on diagnosis and treatment
#274Recombinantly produced allergens
#275Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and HLA-E-bearing composition
#276Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
#277USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS
#278Methods and compositions for attenuating anti-viral transfer vector immune responses
#279Parasitic biological agents for treatment and prevention of graft versus host disease
#280COMPOSITIONS AND METHODS FOR IMMUNE TOLERANCE INDUCTION TO FACTOR VIII REPLACEMENT THERAPIES IN SUBJECTS WITH HEMOPHILIA A
#281Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells
#282Human CTLA4 mutants and use thereof
#283Glycotargeting therapeutics
#284Methods for inducing selective apoptosis
#285Immunotherapeutic molecules and uses thereof
#286Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
#287Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
#288TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES
#289Synthetic membrane-receiver complexes
#290Allograft tolerance induction
#291Cell populations having immunoregulatory activity, method for isolation and uses
#292Method for inducing immune tolerance using non-proliferative polymer-modified allogeneic leukocytes
#293Peptide conjugated particles for the treatment of allergy
#294IgE peptide vaccine
#295Compositions and methods for modulating immune responses
#296Immunoregulatory vaccine
#297Acellular pro-tolerogenic compositions for treatment/prevention of graft rejection
#298Nanoparticles for treatment of allergy
#299Acellular pro-tolerogenic compositions and process for making same
#300Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases